251 related articles for article (PubMed ID: 10717908)
1. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
Domingo RJ; Reilly RM
Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
3. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.
Mohsin H; Jia F; Bryan JN; Sivaguru G; Cutler CS; Ketring AR; Miller WH; Simón J; Frank RK; Theodore LJ; Axworthy DB; Jurisson SS; Lewis MR
Bioconjug Chem; 2011 Dec; 22(12):2444-52. PubMed ID: 22053899
[TBL] [Abstract][Full Text] [Related]
5. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
6. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
7. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
Schott ME; Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Cheng R; Kruper WJ; Fordyce W; Goeckeler W
Cancer; 1994 Feb; 73(3 Suppl):993-8. PubMed ID: 8306291
[TBL] [Abstract][Full Text] [Related]
9. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
10. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
11. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
12. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targeting.
Chinol M; Paganelli G; Sudati F; Meares C; Fazio F
Nucl Med Commun; 1997 Feb; 18(2):176-82. PubMed ID: 9076775
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
Behr TM; Béhé M; Löhr M; Sgouros G; Angerstein C; Wehrmann E; Nebendahl K; Becker W
Eur J Nucl Med; 2000 Jul; 27(7):753-65. PubMed ID: 10952487
[TBL] [Abstract][Full Text] [Related]
19. Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and 111In-DTPA-biocytin.
Alvarez-Diez TM; Polihronis J; Reilly RM
Nucl Med Biol; 1996 May; 23(4):459-66. PubMed ID: 8832700
[TBL] [Abstract][Full Text] [Related]
20. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
